Fig. 6

MUC17 regulates the p38 pathway by interacting with Myh9. a MUC17 co-immunoprecipitated with MYH9 in GC cells. Lysates prepared from Mock-si cells that endogenously expressing MUC17 were precipitated with an anti-MUC17 antibody and the precipitants western blotted with an anti-MYH9 antibody (left). Lysates prepared from T-MUC17 cells that exogenously expressing truncated MUC17 were precipitated with an anti-MUC17 antibody and the precipitants were blotted with an anti-MYH9 antibody (right). b The expression of MYH9 and activation of the RhoA pathway in MUC17 knocked-down AGS cells and control cells (left), and in truncated MUC17 overexpressed MKN45 cells and control cells (right). c The effects of MYH9 on p53 expression and activation of p38 and the RhoA pathway in Mock-si (left) and T-MUC17 cells (right). d The effects of the RhoA pathway inhibitor Y27632 on the expression of MYH9, p53, and activation of p38 pathway in MUC17 knocked-down AGS cells (left) and truncted MUC17 overexpressed MKN45 cells (right). e The effects of p53 on MYH9 expression and activation of p38 and the RhoA pathway in Mock-si (left) and T-MUC17 cells (right). f The expression relation between MUC17 and Myh9 by using TCGA_GC transcriptional database. g Left, Representative images of tumours that originated from Mock-si cells and MUC17-si cells treated with SB203580 or DMSO in Nod Scid mice. Right, Weights of tumors originated from Mock-si cells and MUC17-si cells treated with SB203580 or DMSO from 5 Nod Scid mice (#P > 0.05, **P < 0.001)